NCT07483723 Glucose Profiles in Women With Polycystic Ovary Syndrome
| NCT ID | NCT07483723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Polycystic Ovary Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-01-06 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-01-06 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Polycystic ovary syndrome is a very common condition that is associated with metabolic complications. Patients with polycystic ovary syndrome exhibit insulin resistance and are at greater risk to develop type 2 diabetes. This syndrome is heterogeneous, classified according to 4 phenotypes (A-D). It seems that certain phenotypes are less exposed to insulin resistance and metabolic complications. However, only a few studies have evaluated the glucose profile according to phenotype. New technologies now make it possible to monitor glucose levels continuously. The aim of this project is to evaluate glucose profile parameters using continuous glucose monitoring, and to compare these profiles according to different PCOS phenotypes.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years at inclusion criteria * Patient with polycystic ovary syndrome, defined by the presence of at least 2/3 irregular menstrual cycles, clinical or biological hyperandrogenism, polycystic ovary morphology (pelvic ultrasound) or elevated AMH levels, after the exclusion of other disorders. * Agreed to carry the FSL pro * Signed informed consent Exclusion Criteria: * Pregnancy, breast-feeding * Differential diagnoses: hyperprolactinemia, dysthyroidism, Cushing's syndrome, congenital adrenal hyperplasia, virilizing tumor (ovarian or adrenal), intake of exogenous androgens * Pre-existing diabetes * Patient treated within 3 months prior to inclusion/data collection with estrogen-progestin contraception, progestin contraception, antidiabetic drugs, inositol, antiandrogen
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07483723 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Polycystic Ovary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07483723 currently recruiting?
Yes, NCT07483723 is actively recruiting participants. Contact the research team at Al-Salameh.Abdallah@chu-amiens.fr for enrollment information.
Where is the NCT07483723 trial being conducted?
This trial is being conducted at Salouël, France.
Who is sponsoring the NCT07483723 clinical trial?
NCT07483723 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 80 participants.